Log in
(Ad)
And Reuters magazine calls this type of trading "the new baby boomer hobby." An anonymous trader -- living at the base of the Smoky Mountains -- just released a free report revealing a step-by-step system to generating an extra $5,000 per month in income thanks to this trading strategy. The report is free until Sunday.

NASDAQ:MRTX - Mirati Therapeutics Stock Price, Forecast & News

$97.05
-0.38 (-0.39 %)
(As of 01/19/2020 04:00 PM ET)
Today's Range
$94.35
Now: $97.05
$99.49
50-Day Range
$96.71
MA: $110.86
$128.97
52-Week Range
$55.11
Now: $97.05
$132.59
Volume459,287 shs
Average Volume773,275 shs
Market Capitalization$3.83 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.17
Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRTX
CUSIPN/A
Phone858-332-3410

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.93 million
Book Value$5.86 per share

Profitability

Net Income$-98,420,000.00
Net Margins-2,698.66%

Miscellaneous

Employees63
Market Cap$3.83 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive MRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


Your 401(k) or IRA account could be in double-trouble in 2020! With a slowing global economy and the uncertainty of a national election looming, it's time to PLAY DEFENSE with your hard-earned money. Employ a winning strategy for wealth protection and portfolio diversification to avoid the coming rush of economic risk.

Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics Inc (NASDAQ:MRTX) released its earnings results on Monday, November, 4th. The biotechnology company reported ($1.38) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.25) by $0.13. The biotechnology company earned $0.99 million during the quarter, compared to analysts' expectations of $0.50 million. Mirati Therapeutics had a negative return on equity of 48.60% and a negative net margin of 2,698.66%. View Mirati Therapeutics' Earnings History.

When is Mirati Therapeutics' next earnings date?

Mirati Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Mirati Therapeutics.

What price target have analysts set for MRTX?

16 equities research analysts have issued 12 month target prices for Mirati Therapeutics' stock. Their forecasts range from $81.00 to $130.00. On average, they anticipate Mirati Therapeutics' share price to reach $107.21 in the next year. This suggests a possible upside of 10.5% from the stock's current price. View Analyst Price Targets for Mirati Therapeutics.

What is the consensus analysts' recommendation for Mirati Therapeutics?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mirati Therapeutics.

Has Mirati Therapeutics been receiving favorable news coverage?

News articles about MRTX stock have trended very negative recently, InfoTrie reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mirati Therapeutics earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Mirati Therapeutics.

Are investors shorting Mirati Therapeutics?

Mirati Therapeutics saw a drop in short interest during the month of December. As of December 13th, there was short interest totalling 4,410,000 shares, a drop of 9.4% from the November 28th total of 4,870,000 shares. Based on an average daily volume of 676,400 shares, the days-to-cover ratio is currently 6.5 days. Approximately 11.4% of the shares of the company are short sold. View Mirati Therapeutics' Current Options Chain.

Who are some of Mirati Therapeutics' key competitors?

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Arrowhead Pharmaceuticals (ARWR), Netflix (NFLX), Viking Therapeutics (VKTX), AbbVie (ABBV), Bausch Health Companies (BHC), Advanced Micro Devices (AMD), Amarin (AMRN) and Exelixis (EXEL).

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the folowing people:
  • Dr. Charles M. Baum, Pres, CEO & Director (Age 61)
  • Dr. James Christensen, Chief Scientific Officer & Exec. VP (Age 51)
  • Dr. Isan Chen, Exec. VP and Chief Medical & Devel. Officer (Age 57)
  • Mr. Jamie A. Donadio, Sr. VP & CFO (Age 44)
  • Temre Johnson, Director of Investor Relations & Corp. Communications

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.32%), Tocqueville Asset Management L.P. (0.01%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Jamie A Donadio, Jamie Christensen, Michael G Grey and Venbio Select Advisor Llc. View Institutional Ownership Trends for Mirati Therapeutics.

Which major investors are buying Mirati Therapeutics stock?

MRTX stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Tocqueville Asset Management L.P. and Nisa Investment Advisors LLC. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $97.05.

How big of a company is Mirati Therapeutics?

Mirati Therapeutics has a market capitalization of $3.83 billion and generates $12.93 million in revenue each year. The biotechnology company earns $-98,420,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Mirati Therapeutics employs 63 workers across the globe.View Additional Information About Mirati Therapeutics.

What is Mirati Therapeutics' official website?

The official website for Mirati Therapeutics is http://www.mirati.com/.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]


MarketBeat Community Rating for Mirati Therapeutics (NASDAQ MRTX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  375 (Vote Outperform)
Underperform Votes:  277 (Vote Underperform)
Total Votes:  652
MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe MRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel